Active — Not RecruitingPhase 3

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Japan18 participantsStarted 2024-03-19

Plain-language summary

The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 61 weeks including 52 weeks of study treatment. During the study, participants will visit their study clinic for multiple times.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. A diagnosis of GPP or EP prior to the screening visit.
✓. Candidate for phototherapy or systemic therapy.

Exclusion criteria

✕. Other forms of psoriasis.
✕. History of recent infection.
✕. Any prior exposure to TAK-279, or participation in any study that included a TYK2 inhibitor.

What they're measuring

Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 16

Timeframe: Baseline, Week 16

Percentage of Participants Achieving ≥75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 16

Timeframe: Baseline, Week 16

Trial details

NCT IDNCT06323356

SponsorTakeda

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-10-15

View on ClinicalTrials.gov More Generalized Pustular Psoriasis trials